Form 4: Sionna Therapeutics Director Booth Reports Conversion of Preferred Stock and Share Purchases Following IPO

Director Bruce Booth reports the conversion of preferred stock to common stock and purchases of common stock following Sionna Therapeutics' initial public offering.

Summary

• Bruce Booth, a director of Sionna Therapeutics, filed a Form 4 detailing changes in beneficial ownership of the company's securities on February 10, 2025.
• The filing reports the automatic conversion of Series Seed, Series A, Series B, and Series C convertible preferred stock into common stock at a ratio of one-for-1.4611 upon the closing of Sionna Therapeutics' IPO on February 10, 2025.
• Booth also reported the purchase of 60,000 shares of common stock at a price of $18 per share.
• The shares are held indirectly through Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P.
• Booth disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The document primarily reflects standard post-IPO transactions. The director's share purchase is a positive signal, but overall the sentiment is neutral.

Positives

• The conversion of preferred stock to common stock simplifies the company's capital structure following the IPO.
• The purchase of shares by a director signals confidence in the company's future prospects.

Future Outlook

Not explicitly stated, but the transactions suggest confidence in the company's prospects following the IPO.

Industry Context

Following an IPO, it's common for insiders to adjust their holdings, often through conversion of preferred shares to common shares. This filing reflects that process.

Stakeholder Impact

• The conversion of preferred stock to common stock simplifies the capital structure, potentially benefiting all shareholders.
• The director's share purchase could positively influence investor sentiment.

Key Dates